Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 04, 2015 8:22 PM ET

Professional Services

Company Overview of H. Lee Moffitt Cancer Center & Research Institute

Company Overview

H. Lee Moffitt Cancer Center & Research Institute is a not for-profit institution that focuses on prevention and cure of cancer. The institution offers private patient rooms, blood and marrow transplant programs, outpatient treatment programs, patient care, research, and education services. Additionally, it publishes Today's Tomorrows, a community newsletter about cancer care, research, and education. H. Lee Moffitt was founded in 1986 and is based in Tampa, Florida.

10441 University Center Drive

Tampa, FL 33612

United States

Founded in 1986



Key Executives for H. Lee Moffitt Cancer Center & Research Institute

Chief Executive Officer and Center Director
Age: 65
Executive Vice President Applied Science
Vice President of Public Relations and Marketing
Compensation as of Fiscal Year 2015.

H. Lee Moffitt Cancer Center & Research Institute Key Developments

Bristol-Myers Squibb Co. Partners with Moffitt Cancer Center to Advance Immuno-Oncology Research

Bristol-Myers Squibb Co. partnered with Moffitt Cancer Center to advance immuno-oncology research as part of Bristol-Myers' Immuno-Oncology Rare Population Malignancy (I-O RPM) program. Bristol-Myers and Moffitt will conduct various early phase clinical studies. The partnership will foster new Moffitt investigator-initiated studies for rare tumors and gives the faculty opportunity to educate research students about innovative clinical trials.

Signal Genetics, Inc. and Moffitt Cancer Center Enter into Research Agreement in Multiple Myeloma

Signal Genetics, Inc. announced that the company has entered into an agreement with Moffitt Cancer Center to further validate the clinical utility of its MyPRS test in multiple myeloma and its precursor conditions, smoldering multiple myeloma and MGUS (collectively asymptomatic monoclonal gammopathies, or AMG). Signal plans three validation studies with multiple Moffitt investigators, including: Kenneth M. Shain, M.D., Scientific Director of the Moffitt Myeloma Working Group, Melissa Alsina, M.D., Multiple Myeloma Transplant Program Leader, Rachid Baz, M.D., Associate Member of the Malignant Hematology Program and Taiga Nishihori, M.D., Assistant Member of the Blood & Marrow Transplantation Program. Under the agreement, Signal will perform MyPRS testing on patient specimens to better inform key patient management decisions, including the risk of progression from the constellation of AMG disorders to symptomatic multiple myeloma. The parties anticipate starting work in 2015. As the data is collected, Signal and Moffitt anticipate presenting their findings at scientific conferences and publishing in high impact medical journals.

Cancer Genetics, Inc. Enters into Multi-Year Research Collaboration with Moffitt Cancer Center for Genomics-Based Prediction of Side Effects Associated with Chemotherapy

Cancer Genetics, Inc. announced that it has entered into a series of collaborative studies with leading researchers at Moffitt Cancer Center in Tampa, Florida. The studies, led by Moffitt researchers Heather Jim, PhD, Diane Portman, MD, Howard McLeod, PharmD, and Gillian Bell, PharmD will examine a number of genetic variants as predictors for the most common side effects associated with chemotherapy treatment. Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical challenge experienced by over 50% of patients receiving chemotherapy, even when general-purpose prophylactic anti-emetic therapies are prescribed according to clinical guidelines. The first of these collaborative studies will seek to validate and improve existing risk prediction indices of acute and delayed CINV in patients undergoing chemotherapy. This prospective study will determine whether the inclusion of variations in genes involved in the metabolism of anti-emetic drugs improves the ability to accurately predict which patients are more likely to experience side effects from chemotherapy regimens. Tailored anti-emetic treatment in patients at risk of CINV has the potential to significantly reduce incidence, while decreasing CINV-related medical visit costs, which average $40,001 per patient. A second collaboration will examine the role of individual genetic variants in the effectiveness of pain control in cancer. Pain is one of the most difficult symptoms associated with cancer and its treatment. Opioid and non-opioid analgesics and co-analgesics are frequently used to improve pain control, but patients vary considerably in their response to these drugs. This study will include Moffitt cancer patients treated in the outpatient setting and will seek to identify genetic associations for patient-reported pain outcomes.

Similar Private Companies By Industry

Company Name Region
Prime Industrial Recruiters, Inc. United States
Executive Employers United States
National Academy of Sciences United States
Advanced Performance Consulting Group, Inc. United States
Fluor Daniel (NPOSR), Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H. Lee Moffitt Cancer Center & Research Institute, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at